Revance Therapeutics Faces Scrutiny Over Potential Securities Violations

Law Offices of Howard G. Smith Launch Investigation

The Law Offices of Howard G. Smith have initiated an investigation into Revance Therapeutics, Inc. RVNC following concerns regarding possible breaches of federal securities laws.

On September 23, 2024, Revance reported to the U.S. Securities and Exchange Commission that it had received a notice demanding corrections for alleged serious violations. These violations included exceeding approved buffer stock levels and failing to promote and sell Teoxane products, as outlined in their exclusive distribution agreement with Teoxane SA.

Additionally, Revance indicated that due to these issues, a planned tender offer from Crown Laboratories, Inc. would be postponed until at least October 4, 2024.

Following this announcement, Revance’s stock took a hit, dropping $0.44 per share, equivalent to a 7.66% decline, to close at $5.37 on September 23, 2024. This decline negatively affected investors.

Investors who bought Revance securities or have relevant information about these claims are encouraged to contact Howard G. Smith, Esquire, at the Law Offices of Howard G. Smith. He can be reached at 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by phone at (215) 638-4847, or via email at howardsmith@howardsmithlaw.com. For more details, visit their website at www.howardsmithlaw.com.

Please note that this press release may be considered Attorney Advertising in certain jurisdictions under applicable laws and ethical standards.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241015888167/en/